Comparative Pharmacology
Head-to-head clinical analysis: ALPHAGAN versus GUANFACINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHAGAN versus GUANFACINE HYDROCHLORIDE.
ALPHAGAN vs GUANFACINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic receptor agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Selective alpha-2A adrenergic receptor agonist, reducing sympathetic outflow from the CNS, decreasing peripheral vascular resistance and heart rate.
1 drop of 0.1% or 0.15% solution in the affected eye(s) three times daily, approximately 8 hours apart.
Immediate-release: 0.5-2 mg orally once daily at bedtime, titrated from 0.5 mg/day. Extended-release (ER): 1-4 mg orally once daily at bedtime, titrated from 1 mg/day.
None Documented
None Documented
2.5-3.0 hours in adults; in renal impairment, half-life is prolonged (up to 6 hours).
Terminal elimination half-life is 17 hours (range 10–30 hours) in healthy adults; extends to 24–36 hours in chronic kidney disease.
Renal: approximately 70-80% as unchanged drug and metabolites; fecal: 5-10%.
Renal excretion accounts for approximately 80% of the dose (40-50% unchanged, remainder as metabolites); fecal elimination is about 20%.
Category C
Category A/B
Alpha-2 Agonist
Alpha-2 Agonist